82 related articles for article (PubMed ID: 16088847)
1. Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?
Reid JL
J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):15-24. PubMed ID: 16088847
[TBL] [Abstract][Full Text] [Related]
2. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
3. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Díez J
Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
[TBL] [Abstract][Full Text] [Related]
4. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
[TBL] [Abstract][Full Text] [Related]
5. Prospects for the prevention of stroke.
Dahlöf B
J Hypertens Suppl; 2006 Apr; 24(2):S3-9. PubMed ID: 16601558
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
8. [Inhibition of platelet aggregability by ARB].
Fujii S
Nihon Rinsho; 2006 Jul; 64 Suppl 5():502-5. PubMed ID: 16895218
[No Abstract] [Full Text] [Related]
9. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Aulakh GK; Sodhi RK; Singh M
Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
Ribeiro AB
Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
[TBL] [Abstract][Full Text] [Related]
11. Uric acid: role in cardiovascular disease and effects of losartan.
Alderman M; Aiyer KJ
Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Naritomi H; Fujita T; Ito S; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
Hypertens Res; 2008 Feb; 31(2):295-304. PubMed ID: 18360050
[TBL] [Abstract][Full Text] [Related]
15. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system.
Kurtz TW; Pravenec M
Am J Hypertens; 2008 Aug; 21(8):852-9. PubMed ID: 18535538
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.
Cheung BM; Cheung GT; Lauder IJ; Lau CP; Kumana CR
J Hum Hypertens; 2006 Jan; 20(1):37-43. PubMed ID: 16121197
[TBL] [Abstract][Full Text] [Related]
17. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
18. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
19. [Serum uric acid--a cardiovasular risk factor?].
Alderman M; Redfern JS
Ther Umsch; 2004 Sep; 61(9):547-52. PubMed ID: 15493113
[TBL] [Abstract][Full Text] [Related]
20. [Uric acid--more deleterious than we thought?].
Høieggen A; Os I; Kjeldsen SE
Tidsskr Nor Laegeforen; 2005 May; 125(10):1330-2. PubMed ID: 15909004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
